Cargando…
Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients
The prolongation of the QT interval represents the main feature of the long QT syndrome (LQTS), a life-threatening genetic disease. The heterozygous SCN5A V411M mutation of the human sodium channel leads to a LQTS type 3 with severe proarrhythmic effects due to an increase in the late component of t...
Autores principales: | Cano, Jordi, Zorio, Esther, Mazzanti, Andrea, Arnau, Miguel Ángel, Trenor, Beatriz, Priori, Silvia G., Saiz, Javier, Romero, Lucia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845660/ https://www.ncbi.nlm.nih.gov/pubmed/33519442 http://dx.doi.org/10.3389/fphar.2020.580481 |
Ejemplares similares
-
Complexity of ranolazine and phenytoin use in an infant with long QT syndrome type 3
por: Tan, Reina Bianca, et al.
Publicado: (2016) -
Proton-dependent inhibition of the cardiac sodium channel Na(v)1.5 by ranolazine
por: Sokolov, S., et al.
Publicado: (2013) -
Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium Channels
por: Ratte, Antonius, et al.
Publicado: (2019) -
Flecainide and risk of skin neoplasms: Results of a large nested case–control study in Spain and Denmark
por: Reyes, Carlen, et al.
Publicado: (2022) -
Pathogenic in-Frame Variants in SCN8A: Expanding the Genetic Landscape of SCN8A-Associated Disease
por: Wong, Jennifer C., et al.
Publicado: (2021)